Merck announced that its PD-1 inhibitor pembrolizumab (brand name: Keytruda) has been approved by the China National Medical Products Administration (NMPA) for use in combination with trastuzumab, fluoropyrimidine and platinum-based chemotherapy as first-line treatment for locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma in patients whose tumors express PD-L1 (combined positive score (CPS) ≥1) based on data from the global phase III clinical trial KEYNOTE-811.
默沙东帕博利珠单抗胃癌新适应证在华获批
Merck's pembrolizumab has been approved in China for a new indication for gastric cancer.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.